drugset / Trial / NCT01533298

A Safety, Efficacy Study of CombiflexOmega Peri Versus SmofKabiven Peripheral in Patients With Parenteral Nutrition

NCT01533298 ↗

Phase 3 Completed 50 enrolled JW Life Science
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the safety and efficacy of CombiflexOmega peri in comparison to SmofKabiven peripheral in postoperative patients requiring parenteral nutrition.

Timeline

Start
2011-07
Primary completion
2011-12
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CombiflexOmega peri Unknown — Intravenous
Comparator SmofKabiven Peripheral Unknown — Intravenous

Indications

No indication recorded.